{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:09:34Z","timestamp":1779120574547,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research Foundation of a Korea (NRF) funded by the Ministry of Education","award":["NRF-2018R1D1A1B07043031"],"award-info":[{"award-number":["NRF-2018R1D1A1B07043031"]}]},{"name":"National Research Foundation of a Korea (NRF) funded by the Ministry of Science and ICT","award":["2011-0030001"],"award-info":[{"award-number":["2011-0030001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The prognostic value of current multigene assays for breast cancer is limited to hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer. Despite the prognostic significance of immune response-related genes in breast cancer, immune gene signatures have not been incorporated into most multigene assays. Here, using public gene expression microarray datasets, we classified breast cancer patients into three risk groups according to clinical risk and proliferation risk. We then developed the immune prognostic index based on expression of five immune response-related genes (<jats:italic>TRAT1<\/jats:italic>, <jats:italic>IL2RB, CTLA4<\/jats:italic>, <jats:italic>IGHM<\/jats:italic> and <jats:italic>IL21R<\/jats:italic>) and lymph node status to predict the risk of recurrence in the clinical and proliferation high-risk (CPH) group. The 10-year probability of disease-free survival (DFS) or distant metastasis-free survival (DMFS) of patients classified as high risk according to the immune prognostic index was significantly lower than those of patients classified as intermediate or low risk. Multivariate analysis revealed that the index is an independent prognostic factor for DFS or DMFS. Moreover, the C-index revealed that it is superior to clinicopathological variables for predicting prognosis. Its prognostic significance was also validated in independent datasets. The immune prognostic index identified low-risk patients among patients classified as CPH, regardless of the molecular subtype of breast cancer, and may overcome the limitations of current multigene assays.<\/jats:p>","DOI":"10.1038\/s41598-020-80274-5","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T06:13:01Z","timestamp":1610086381000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A novel immune prognostic index for stratification of high-risk patients with early breast cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Hannah","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Jeong","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beom-Mo","family":"Koo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Geon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinil","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Kee","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"80274_CR1","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817\u20132826. https:\/\/doi.org\/10.1056\/NEJMoa041588 (2004).","journal-title":"N. Engl. J. Med."},{"key":"80274_CR2","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/415530a","volume":"415","author":"LJ van\u2019t Veer","year":"2002","unstructured":"van\u2019t Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530\u2013536. https:\/\/doi.org\/10.1038\/415530a (2002).","journal-title":"Nature"},{"key":"80274_CR3","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/jco.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160\u20131167. https:\/\/doi.org\/10.1200\/jco.2008.18.1370 (2009).","journal-title":"J. Clin. Oncol."},{"key":"80274_CR4","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1158\/1078-0432.Ccr-11-0926","volume":"17","author":"M Filipits","year":"2011","unstructured":"Filipits, M. et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res. 17, 6012\u20136020. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-0926 (2011).","journal-title":"Clin. Cancer Res."},{"key":"80274_CR5","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","volume":"24","author":"S Paik","year":"2006","unstructured":"Paik, S. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726\u20133734. https:\/\/doi.org\/10.1200\/JCO.2005.04.7985 (2006).","journal-title":"J. Clin. Oncol."},{"key":"80274_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","volume":"11","author":"KS Albain","year":"2010","unstructured":"Albain, K. S. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11, 55\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(09)70314-6 (2010).","journal-title":"Lancet Oncol."},{"key":"80274_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano, J. A. et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N. Engl. J. Med. 379, 111\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa1804710 (2018).","journal-title":"N. Engl. J. Med."},{"key":"80274_CR8","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso, F. et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N. Engl. J. Med. 375, 717\u2013729. https:\/\/doi.org\/10.1056\/NEJMoa1602253 (2016).","journal-title":"N. Engl. J. Med."},{"key":"80274_CR9","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","volume":"26","author":"AS Coates","year":"2015","unstructured":"Coates, A. S. et al. Tailoring therapies\u2013improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann. Oncol. 26, 1533\u20131546. https:\/\/doi.org\/10.1093\/annonc\/mdv221 (2015).","journal-title":"Ann. Oncol."},{"key":"80274_CR10","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1200\/JCO.2015.65.2289","volume":"34","author":"LN Harris","year":"2016","unstructured":"Harris, L. N. et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: american society of clinical oncology clinical practice guideline. J. Clin. Oncol. 34, 1134\u20131150. https:\/\/doi.org\/10.1200\/JCO.2015.65.2289 (2016).","journal-title":"J. Clin. Oncol."},{"key":"80274_CR11","doi-asserted-by":"publisher","first-page":"e1100","DOI":"10.7759\/cureus.1100","volume":"9","author":"D Tiberi","year":"2017","unstructured":"Tiberi, D. et al. Limitations of personalized medicine and gene assays for breast cancer. Cureus 9, e1100. https:\/\/doi.org\/10.7759\/cureus.1100 (2017).","journal-title":"Cureus"},{"key":"80274_CR12","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1158\/1078-0432.CCR-16-2633","volume":"23","author":"AH Partridge","year":"2017","unstructured":"Partridge, A. H. & Carey, L. A. Unmet needs in clinical research in breast cancer: where do we need to go?. Clin. Cancer Res. 23, 2611\u20132616. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2633 (2017).","journal-title":"Clin. Cancer Res."},{"key":"80274_CR13","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/ijc.32139","volume":"145","author":"Z Varga","year":"2019","unstructured":"Varga, Z., Sinn, P. & Seidman, A. D. Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score(R) (RS) assay and other genomic assays for early breast cancer. Int. J. Cancer 145, 882\u2013893. https:\/\/doi.org\/10.1002\/ijc.32139 (2019).","journal-title":"Int. J. Cancer"},{"key":"80274_CR14","doi-asserted-by":"publisher","first-page":"5158","DOI":"10.1158\/1078-0432.CCR-07-4756","volume":"14","author":"C Desmedt","year":"2008","unstructured":"Desmedt, C. et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 14, 5158\u20135165. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4756 (2008).","journal-title":"Clin. Cancer Res."},{"key":"80274_CR15","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1158\/1078-0432.Ccr-14-3127","volume":"21","author":"I Gingras","year":"2015","unstructured":"Gingras, I., Desmedt, C., Ignatiadis, M. & Sotiriou, C. CCR 20th anniversary commentary: gene-expression signature in breast cancer-where did it start and where are we now?. Clin. Cancer Res. 21, 4743\u20134746. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-3127 (2015).","journal-title":"Clin. Cancer Res."},{"key":"80274_CR16","doi-asserted-by":"publisher","first-page":"R85","DOI":"10.1186\/bcr2753","volume":"12","author":"C Yau","year":"2010","unstructured":"Yau, C. et al. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res. 12, R85. https:\/\/doi.org\/10.1186\/bcr2753 (2010).","journal-title":"Breast Cancer Res."},{"key":"80274_CR17","doi-asserted-by":"publisher","first-page":"R103","DOI":"10.1186\/bcr3567","volume":"15","author":"C Yau","year":"2013","unstructured":"Yau, C. et al. An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk. Breast Cancer Res. BCR 15, R103\u2013R103. https:\/\/doi.org\/10.1186\/bcr3567 (2013).","journal-title":"Breast Cancer Res. BCR"},{"key":"80274_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10549-017-4234-4","volume":"164","author":"J Han","year":"2017","unstructured":"Han, J. et al. MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer. Breast Cancer Res. Treat. 164, 41\u201356. https:\/\/doi.org\/10.1007\/s10549-017-4234-4 (2017).","journal-title":"Breast Cancer Res. Treat."},{"key":"80274_CR19","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.1158\/0008-5472.CAN-07-5206","volume":"68","author":"M Schmidt","year":"2008","unstructured":"Schmidt, M. et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 68, 5405\u20135413. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-5206 (2008).","journal-title":"Cancer Res."},{"key":"80274_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41523-018-0088-0","volume":"4","author":"B Yang","year":"2018","unstructured":"Yang, B. et al. An assessment of prognostic immunity markers in breast cancer. NPJ Breast Cancer 4, 35. https:\/\/doi.org\/10.1038\/s41523-018-0088-0 (2018).","journal-title":"NPJ Breast Cancer"},{"key":"80274_CR21","doi-asserted-by":"publisher","first-page":"R157","DOI":"10.1186\/gb-2007-8-8-r157","volume":"8","author":"AE Teschendorff","year":"2007","unstructured":"Teschendorff, A. E., Miremadi, A., Pinder, S. E., Ellis, I. O. & Caldas, C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 8, R157. https:\/\/doi.org\/10.1186\/gb-2007-8-8-r157 (2007).","journal-title":"Genome Biol."},{"key":"80274_CR22","doi-asserted-by":"publisher","first-page":"R97","DOI":"10.1186\/bcr3035","volume":"13","author":"A Rody","year":"2011","unstructured":"Rody, A. et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res. 13, R97. https:\/\/doi.org\/10.1186\/bcr3035 (2011).","journal-title":"Breast Cancer Res."},{"key":"80274_CR23","doi-asserted-by":"publisher","first-page":"R73","DOI":"10.1186\/bcr2138","volume":"10","author":"AE Teschendorff","year":"2008","unstructured":"Teschendorff, A. E. & Caldas, C. A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res. 10, R73. https:\/\/doi.org\/10.1186\/bcr2138 (2008).","journal-title":"Breast Cancer Res."},{"key":"80274_CR24","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1158\/0008-5472.Can-08-4013","volume":"69","author":"M Schmidt","year":"2009","unstructured":"Schmidt, M., Hengstler, J. G., von Torne, C., Koelbl, H. & Gehrmann, M. C. Coordinates in the universe of node-negative breast cancer revisited. Cancer Res. 69, 2695\u20132698. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-4013 (2009).","journal-title":"Cancer Res."},{"key":"80274_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10549-011-1626-8","volume":"132","author":"E Oh","year":"2012","unstructured":"Oh, E. et al. A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity. Breast Cancer Res. Treat. 132, 499\u2013509. https:\/\/doi.org\/10.1007\/s10549-011-1626-8 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"80274_CR26","doi-asserted-by":"publisher","first-page":"45554","DOI":"10.1038\/srep45554","volume":"7","author":"G Gong","year":"2017","unstructured":"Gong, G. et al. A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+\/HER2- early breast cancer. Sci. Rep. 7, 45554\u201345554. https:\/\/doi.org\/10.1038\/srep45554 (2017).","journal-title":"Sci. Rep."},{"key":"80274_CR27","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s10549-011-1470-x","volume":"131","author":"ML Ascierto","year":"2012","unstructured":"Ascierto, M. L. et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res. Treat. 131, 871\u2013880. https:\/\/doi.org\/10.1007\/s10549-011-1470-x (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"80274_CR28","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3389\/fimmu.2018.01209","volume":"9","author":"J Yeong","year":"2018","unstructured":"Yeong, J. et al. High densities of tumor-associated plasma cells predict improved prognosis in triple negative breast cancer. Front. Immunol. 9, 1209. https:\/\/doi.org\/10.3389\/fimmu.2018.01209 (2018).","journal-title":"Front. Immunol."},{"key":"80274_CR29","doi-asserted-by":"publisher","first-page":"5938","DOI":"10.1158\/0008-5472.Can-17-1007","volume":"77","author":"Y Jounaidi","year":"2017","unstructured":"Jounaidi, Y., Cotten, J. F., Miller, K. W. & Forman, S. A. Tethering IL2 to its receptor IL2Rbeta enhances antitumor activity and expansion of natural killer NK92 cells. Cancer Res. 77, 5938\u20135951. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-1007 (2017).","journal-title":"Cancer Res."},{"key":"80274_CR30","doi-asserted-by":"publisher","first-page":"20429","DOI":"10.1073\/pnas.0905139106","volume":"106","author":"D Bogunovic","year":"2009","unstructured":"Bogunovic, D. et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc. Natl. Acad. Sci. USA 106, 20429\u201320434. https:\/\/doi.org\/10.1073\/pnas.0905139106 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"80274_CR31","first-page":"211","volume":"12","author":"LN Wang","year":"2015","unstructured":"Wang, L. N., Cui, Y. X., Ruge, F. & Jiang, W. G. Interleukin 21 and its receptor play a role in proliferation, migration and invasion of breast cancer cells. Cancer Genom. Proteom. 12, 211\u2013221 (2015).","journal-title":"Cancer Genom. Proteom."},{"key":"80274_CR32","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/0008-5472.Can-15-1567","volume":"76","author":"D Mittal","year":"2016","unstructured":"Mittal, D. et al. Improved treatment of breast cancer with anti-HER2 therapy requires interleukin-21 signaling in CD8+T cells. Cancer Res. 76, 264\u2013274. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-1567 (2016).","journal-title":"Cancer Res."},{"key":"80274_CR33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/86297","volume":"2","author":"MJ Smyth","year":"2001","unstructured":"Smyth, M. J., Godfrey, D. I. & Trapani, J. A. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2, 293\u2013299. https:\/\/doi.org\/10.1038\/86297 (2001).","journal-title":"Nat. Immunol."},{"key":"80274_CR34","doi-asserted-by":"publisher","first-page":"728","DOI":"10.2174\/156800910793605811","volume":"10","author":"H Mao","year":"2010","unstructured":"Mao, H. et al. New insights of CTLA-4 into its biological function in breast cancer. Curr. Cancer Drug Targets 10, 728\u2013736 (2010).","journal-title":"Curr. Cancer Drug Targets"},{"key":"80274_CR35","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00262-015-1696-2","volume":"64","author":"H Yu","year":"2015","unstructured":"Yu, H. et al. Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis. Cancer Immunol. Immunother. 64, 853\u2013860. https:\/\/doi.org\/10.1007\/s00262-015-1696-2 (2015).","journal-title":"Cancer Immunol. Immunother."},{"key":"80274_CR36","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/1078-0432.Ccr-07-1658","volume":"14","author":"MC Cheang","year":"2008","unstructured":"Cheang, M. C. et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 14, 1368\u20131376. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-1658 (2008).","journal-title":"Clin. Cancer Res."},{"key":"80274_CR37","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882\u2013883. https:\/\/doi.org\/10.1093\/bioinformatics\/bts034 (2012).","journal-title":"Bioinformatics"},{"key":"80274_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"W da Huang","year":"2009","unstructured":"da Huang, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44\u201357. https:\/\/doi.org\/10.1038\/nprot.2008.211 (2009).","journal-title":"Nat. Protoc."},{"key":"80274_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkn923","volume":"37","author":"W da Huang","year":"2009","unstructured":"da Huang, W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucl. Acids Res. 37, 1\u201313. https:\/\/doi.org\/10.1093\/nar\/gkn923 (2009).","journal-title":"Nucl. Acids Res."},{"key":"80274_CR40","doi-asserted-by":"publisher","first-page":"e88309","DOI":"10.1371\/journal.pone.0088309","volume":"9","author":"DM Wolf","year":"2014","unstructured":"Wolf, D. M., Lenburg, M. E., Yau, C., Boudreau, A. & van\u2019t Veer, L. J. Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity. PLoS ONE 9, e88309. https:\/\/doi.org\/10.1371\/journal.pone.0088309 (2014).","journal-title":"PLoS ONE"},{"key":"80274_CR41","first-page":"73","volume":"2","author":"T Hothorn","year":"2002","unstructured":"Hothorn, T. & Lausen, B. Maximally selected rank statistics in R. Biometrics 2, 73\u201385 (2002).","journal-title":"Biometrics"},{"key":"80274_CR42","first-page":"1","volume":"39","author":"S Noah","year":"2011","unstructured":"Noah, S., Jerome, F., Hastie, T. & Tibshirani, R. Regularization paths for Cox\u2019s proportional hazards model via coordinate descent. J. Stat. Softw. 39, 1 (2011).","journal-title":"J. Stat. Softw."},{"key":"80274_CR43","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(sici)1097-0258(19960229)15:4<361::Aid-sim168>3.0.Co;2-4","volume":"15","author":"FE Harrell Jr","year":"1996","unstructured":"Harrell, F. E. Jr., Lee, K. L. & Mark, D. B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15, 361\u2013387. https:\/\/doi.org\/10.1002\/(sici)1097-0258(19960229)15:4%3c361::Aid-sim168%3e3.0.Co;2-4 (1996).","journal-title":"Stat. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80274-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80274-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80274-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T19:56:30Z","timestamp":1670010990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80274-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["80274"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-80274-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"assertion":[{"value":"14 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JH is a salaried employee of Gencurix. HL and YKS hold a patent application related to the content of this article. The other authors have no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}